Abstract
This report describes the effect of administration (n=3) or withdrawal (n=2) of canagliflozin,
a sodium-glucose co-transporters 2 (SGLT-2) inhibitor, on cardiac function in relation
to ketone bodies. Three cases received and two cases discontinued canagliflozin. Changes
of heart function with ultrasonography (EF: ejection fraction and %FS: functional
shortening) and cardiometabolic parameters including ketone bodies (acetoacetate/beta-hydroxybutylate)
were compared at 3 months. 69, 68 and 60 years old male patients A, B and C, respectively
with moderately decreased heart function received canagliflozin 100 mg/day. EF, %FS
and acetoacetate/beta-hydroxybutylate levels increased. 60 and 59 years old female
patients D and E with normal and borderline heart function, respectively discontinued
canagliflozin 50 mg/day. EF, %FS and acetoacetate/beta-hydroxybutylate levels decreased.
Taken together, these results suggest that concomitant changes between ketone bodies
and heart function were observed with or without canagliflzoin. This drug might have
effects on cardiac function through modulating ketone bodies.
Key words
SGLT-2 inhibitors - canagliflozin - ketone body - heart function
